Noninvasive assessment of cancer response to therapy.
Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.
Han
Zhaozhong
Z
Department of Radiation Oncology, School of Medicine, Vanderbilt University, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
Fu
Allie
A
Wang
Hailun
H
Diaz
Roberto
R
Geng
Ling
L
Onishko
Halina
H
Hallahan
Dennis E
DE
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000737:chemistry / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy*; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D010455:Peptides